Login Register Cart 0
Review Article

重新利用西洛他唑治疗雷诺现象

卷 28, 期 12, 2021

发表于: 03 September, 2020

页: [2409 - 2417] 页: 9

弟呕挨: 10.2174/0929867327666200903114154

价格: $65

Open Access Journals Promotions 2
摘要

雷诺现象(RP)的结果夸大的寒冷诱导血管收缩。RP患者血管痉挛发作，手指血流灌注不足，导致手指水平三色变化。严重的RP可能导致溃疡并威胁组织的生存能力。许多药物已被用于缓解RP的症状。这些药物包括钙通道阻滞剂、cGMP特异性磷酸二酯酶5型抑制剂、前列环素类似物和血管紧张素受体阻滞剂。尽管这些药物种类繁多，但它们不能治疗RP，而只能减轻其症状。到目前为止，美国食品和药物管理局还没有批准治疗RP的药物。西洛他唑是磷酸二酯酶iii的选择性抑制剂，最初用于治疗间歇性跛行。由于它的抗血小板和血管扩张特性，西洛他唑正被重新用作一种潜在的RP药物。本文就西洛他唑增强RP患者血液灌注的不同作用线作一综述。

关键词: 心血管疾病，西洛他唑，手指缺血，药物再利用，雷诺氏现象，冷诱导的血管收缩

« Previous Next »
[1]
Vane, J.R. The fight against rheumatism: from willow bark to COX-1 sparing drugs. J. Physiol. Pharmacol., 2000, 51(4 Pt 1), 573-586.
[PMID: 11192932]
[2]
Desborough, M.J.R.; Keeling, D.M. The aspirin story - from willow to wonder drug. Br. J. Haematol., 2017, 177(5), 674-683.
[http://dx.doi.org/10.1111/bjh.14520] [PMID: 28106908]
[3]
Flemming, A. Cancer: Of targets and anti-targets. Nat. Rev. Drug Discov., 2012, 11(7), 515.
[http://dx.doi.org/10.1038/nrd3781] [PMID: 22722534]
[4]
Jourdan, J.P.; Bureau, R.; Rochais, C.; Dallemagne, P. Drug repositioning: a brief overview. J. Pharm. Pharmacol., 2020.
[http://dx.doi.org/10.1111/jphp.13273] [PMID: 32301512]
[5]
Holstein, S.A.; McCarthy, P.L. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs, 2017, 77(5), 505-520.
[http://dx.doi.org/10.1007/s40265-017-0689-1] [PMID: 28205024]
[6]
Kale, V.P.; Habib, H.; Chitren, R.; Patel, M.; Pramanik, K.C.; Jonnalagadda, S.C.; Challagundla, K.; Pandey, M.K. Old drugs, new uses: drug repurposing in hematological malignancies. Semin. Cancer Biol., 2020, 68, 242-248.
[http://dx.doi.org/10.1016/j.semcancer.2020.03.005] [PMID: 32151704]
[7]
Goldstein, I.; Burnett, A.L.; Rosen, R.C.; Park, P.W.; Stecher, V.J. The serendipitous story of sildenafil: an unexpected oral therapy for erectile dysfunction. Sex. Med. Rev., 2019, 7(1), 115-128.
[http://dx.doi.org/10.1016/j.sxmr.2018.06.005] [PMID: 30301707]
[8]
Kass, D.A.; Champion, H.C.; Beavo, J.A. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ. Res., 2007, 101(11), 1084-1095.
[http://dx.doi.org/10.1161/CIRCRESAHA.107.162511] [PMID: 18040025]
[9]
Gelosa, P.; Castiglioni, L.; Camera, M.; Sironi, L. Drug repurposing in cardiovascular diseases: Opportunity or hopeless dream? Biochem. Pharmacol., 2020, 177, 113894.
[http://dx.doi.org/10.1016/j.bcp.2020.113894] [PMID: 32142728]
[10]
Dudley, J.; Berliocchi, L. Drug repositioning: approaches and applications for neurotherapeutics; CRC press: Boca Raton, 2017, Vol. 1, .
[http://dx.doi.org/10.4324/9781315373669]
[11]
Landry, G.J. Current medical and surgical management of Raynaud’s syndrome. J. Vasc. Surg., 2013, 57(6), 1710-1716.
[http://dx.doi.org/10.1016/j.jvs.2013.03.012] [PMID: 23618525]
[12]
Herrick, A.L. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat. Rev. Rheumatol., 2012, 8(8), 469-479.
[http://dx.doi.org/10.1038/nrrheum.2012.96] [PMID: 22782008]
[13]
Pauling, J.D.; Hughes, M.; Pope, J.E. Raynaud’s phenomenon-an update on diagnosis, classification and management. Clin. Rheumatol., 2019, 38(12), 3317-3330.
[http://dx.doi.org/10.1007/s10067-019-04745-5] [PMID: 31420815]
[14]
Block, J.A.; Sequeira, W. Raynaud’s phenomenon. Lancet, 2001, 357(9273), 2042-2048.
[http://dx.doi.org/10.1016/S0140-6736(00)05118-7] [PMID: 11438158]
[15]
Prete, M.; Fatone, M.C.; Favoino, E.; Perosa, F. Raynaud’s phenomenon: from molecular pathogenesis to therapy. Autoimmun. Rev., 2014, 13(6), 655-667.
[http://dx.doi.org/10.1016/j.autrev.2013.12.001] [PMID: 24418302]
[16]
Fardoun, M.M.; Nassif, J.; Issa, K.; Baydoun, E.; Eid, A.H. Raynaud’s phenomenon: a brief review of the underlying mechanisms. Front. Pharmacol., 2016, 7, 438.
[http://dx.doi.org/10.3389/fphar.2016.00438] [PMID: 27899893]
[17]
Lis-Święty, A. Recent advances in the workup and management of Raynaud phenomenon Pol. Arch. Intern. Med., 2019, 129(11), 798-808.
[http://dx.doi.org/10.20452/pamw.15008] [PMID: 31577265]
[18]
Bakst, R.; Merola, J.F.; Franks, A.G., Jr; Sanchez, M. Raynaud’s phenomenon: pathogenesis and management. J. Am. Acad. Dermatol., 2008, 59(4), 633-653.
[http://dx.doi.org/10.1016/j.jaad.2008.06.004] [PMID: 18656283]
[19]
Sama, C-B. Post-traumatic dgital gangrene associated with epinephrine use in primary Raynaud’s phenomenon: lesson for the future. Ethiop. J. Health Sci., 2016, 26(4), 401-404.
[http://dx.doi.org/10.4314/ejhs.v26i4.13] [PMID: 27587939]
[20]
Charkoudian, N. Mechanisms and modifiers of reflex induced cutaneous vasodilation and vasoconstriction in humans. J. Appl. Physiol., 2010, 109(4), 1221-1228.
[http://dx.doi.org/10.1152/japplphysiol.00298.2010] [PMID: 20448028]
[21]
Wigley, F.M.; Flavahan, N.A. Raynaud’s Phenomenon. N. Engl. J. Med., 2016, 375(6), 556-565.
[http://dx.doi.org/10.1056/NEJMra1507638] [PMID: 27509103]
[22]
Chotani, M.A.; Flavahan, S.; Mitra, S.; Daunt, D.; Flavahan, N.A. Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am. J. Physiol. Heart Circ. Physiol., 2000, 278(4), H1075-H1083.
[http://dx.doi.org/10.1152/ajpheart.2000.278.4.H1075] [PMID: 10749700]
[23]
MacDonald, E.; Kobilka, B.K.; Scheinin, M. Gene targeting--homing in on α 2-adrenoceptor-subtype function. Trends Pharmacol. Sci., 1997, 18(6), 211-219.
[http://dx.doi.org/10.1016/S0165-6147(97)01063-8] [PMID: 9227000]
[24]
von Zastrow, M.; Kobilka, B.K. Antagonist-dependent and -independent steps in the mechanism of adrenergic receptor internalization. J. Biol. Chem., 1994, 269(28), 18448-18452.
[PMID: 7518433 ]
[25]
Bailey, S.R.; Eid, A.H.; Mitra, S.; Flavahan, S.; Flavahan, N.A. Rho kinase mediates cold-induced constriction of cutaneous arteries: role of α2C-adrenoceptor translocation. Circ. Res., 2004, 94(10), 1367-1374.
[http://dx.doi.org/10.1161/01.RES.0000128407.45014.58] [PMID: 15087420]
[26]
Jeyaraj, S.C.; Chotani, M.A.; Mitra, S.; Gregg, H.E.; Flavahan, N.A.; Morrison, K.J. Cooling evokes redistribution of α2C-adrenoceptors from golgi to plasma membrane in transfected human embryonic kidney 293 cells. Mol. Pharmacol., 2001, 60(6), 1195-1200.
[http://dx.doi.org/10.1124/mol.60.6.1195] [PMID: 11723226]
[27]
Jeyaraj, S.C.; Unger, N.T.; Eid, A.H.; Mitra, S.; Paul El-Dahdah, N.; Quilliam, L.A.; Flavahan, N.A.; Chotani, M.A. Cyclic AMP-Rap1A signaling activates RhoA to induce α(2c)-adrenoceptor translocation to the cell surface of microvascular smooth muscle cells. Am. J. Physiol. Cell Physiol., 2012, 303(5), C499-C511.
[http://dx.doi.org/10.1152/ajpcell.00461.2011] [PMID: 22621783]
[28]
Eid, A.H.; Chotani, M.A.; Mitra, S.; Miller, T.J.; Flavahan, N.A. Cyclic AMP acts through Rap1 and JNK signaling to increase expression of cutaneous smooth muscle alpha(2C)-adrenoceptors. Am. J. Physiol. Heart Circ. Physiol., 2008, 295(1), H266-H272.
[http://dx.doi.org/10.1152/ajpheart.00084.2008] [PMID: 18487435]
[29]
Halawa, B. Calcium channel blockers in the treatment of cardiovascular disease. Pol. Merkur. Lekarski., 2001, 11(61), 83-87.
[PMID: 11579840]
[30]
Sturgill, M.G.; Seibold, J.R. Rational use of calcium-channel antagonists in Raynaud’s phenomenon. Curr. Opin. Rheumatol., 1998, 10(6), 584-588.
[http://dx.doi.org/10.1097/00002281-199811000-00013] [PMID: 9812220]
[31]
Rirash, F.; Tingey, P.C.; Harding, S.E.; Maxwell, L.J.; Tanjong Ghogomu, E.; Wells, G.A.; Tugwell, P.; Pope, J. Calcium channel blockers for primary and secondary Raynaud’s phenomenon. Cochrane Database Syst. Rev., 2017. 12CD000467.
[http://dx.doi.org/10.1002/14651858.CD000467.pub2] [PMID: 29237099]
[32]
Ennis, H.; Hughes, M.; Anderson, M.E.; Wilkinson, J.; Herrick, A.L. Calcium channel blockers for primary Raynaud’s phenomenon. Cochrane Database Syst. Rev., 2016. 2CD002069.
[http://dx.doi.org/10.1002/14651858.CD002069.pub5] [PMID: 26914257]
[33]
Negrini, S.; Magnani, O.; Matucci-Cerinic, M.; Carignola, R.; Data, V.; Montabone, E.; Santaniello, A.; Adorni, G.; Murdaca, G.; Puppo, F.; Indiveri, F.; Della Rossa, A.; D’Ascanio, A.; Barsotti, S.; Giuggioli, D.; Ferri, C.; Lumetti, F.; Bosello, S.L.; Canestrari, G.; Bellando Randone, S.; Bruni, C.; Guiducci, S.; Battaglia, E.; De Andres, M.I.; Russo, A.A.; Beretta, L. Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. Clin. Exp. Med., 2019, 19(3), 357-366.
[http://dx.doi.org/10.1007/s10238-019-00553-y] [PMID: 30989453]
[34]
Lee, E.Y.; Park, J.K.; Lee, W.; Kim, Y.K.; Park, C.S.; Giles, J.T.; Park, J.W.; Shin, K.; Lee, J.S.; Song, Y.W.; Lee, E.B. Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud’s phenomenon: a double-blind, randomized, cross-over study. Rheumatology (Oxford), 2014, 53(4), 658-664.
[http://dx.doi.org/10.1093/rheumatology/ket417] [PMID: 24352340]
[35]
Temprano, K.K. A review of raynaud’s disease. Mo. Med., 2016, 113(2), 123-126.
[PMID: 27311222]
[36]
Regulski, M.; Regulska, K.; Stanisz, B.J.; Murias, M.; Gieremek, P.; Wzgarda, A.; Niznik, B. Chemistry and pharmacology of angiotensin-converting enzyme inhibitors. Curr. Pharm. Des., 2015, 21(13), 1764-1775.
[http://dx.doi.org/10.2174/1381612820666141112160013] [PMID: 25388457]
[37]
Linnemann, B.; Erbe, M. Raynaud’s phenomenon and digital ischaemia--pharmacologic approach and alternative treatment options. Vasa, 2016, 45(3), 201-212.
[http://dx.doi.org/10.1024/0301-1526/a000526] [PMID: 27129065]
[38]
Agustí, A.; Bonet, S.; Arnau, J.M.; Vidal, X.; Laporte, J.R. Adverse effects of ACE inhibitors in patients with chronic heart failure and/or ventricular dysfunction: meta-analysis of randomised clinical trials. Drug Saf., 2003, 26(12), 895-908.
[http://dx.doi.org/10.2165/00002018-200326120-00004] [PMID: 12959631]
[39]
Wigley, F.M. Clinical practice. Raynaud’s phenomenon. N. Engl. J. Med., 2002, 347(13), 1001-1008.
[http://dx.doi.org/10.1056/NEJMcp013013] [PMID: 12324557]
[40]
Dindyal, S.; Kyriakides, C. A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy. Recent Pat. Cardiovasc. Drug Discov., 2009, 4(1), 6-14.
[http://dx.doi.org/10.2174/157489009787260025] [PMID: 19149700]
[41]
Orange book: approved drug products with therapeutic equivalence evaluations. Available at: https://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm(acceesed on: 24 March, 2021)
[42]
Cariski, A.T. Cilostazol: a novel treatment option in intermittent claudication. Int. J. Clin. Pract. Suppl., 2001, (119), 11-18.
[PMID: 11355274]
[43]
Bedenis, R.; Stewart, M.; Cleanthis, M.; Robless, P.; Mikhailidis, D.P.; Stansby, G. Cilostazol for intermittent claudication. Cochrane Database Syst. Rev., 2014, 2014(10), CD003748.
[http://dx.doi.org/10.1002/14651858.cd003748.pub4] [PMID: 25358850]
[44]
Yentes, J.M.; Huisinga, J.M.; Myers, S.A.; Pipinos, I.I.; Johanning, J.M.; Stergiou, N. Pharmacological treatment of intermittent claudication does not have a significant effect on gait impairments during claudication pain. J. Appl. Biomech., 2012, 28(2), 184-191.
[http://dx.doi.org/10.1123/jab.28.2.184] [PMID: 22723116]
[45]
Shinohara, Y.; Katayama, Y.; Uchiyama, S.; Yamaguchi, T.; Handa, S.; Matsuoka, K.; Ohashi, Y.; Tanahashi, N.; Yamamoto, H.; Genka, C.; Kitagawa, Y.; Kusuoka, H.; Nishimaru, K.; Tsushima, M.; Koretsune, Y.; Sawada, T.; Hamada, C. CSPS 2 group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol., 2010, 9(10), 959-968.
[http://dx.doi.org/10.1016/S1474-4422(10)70198-8] [PMID: 20833591]
[46]
Kim, S.M.; Jung, J.M.; Kim, B.J.; Lee, J.S.; Kwon, S.U. Cilostazol mono and combination treatments in ischemic stroke: an updated systematic review and meta-analysis. Stroke, 2019, 50(12), 3503-3511.
[http://dx.doi.org/10.1161/STROKEAHA.119.026655] [PMID: 31607242]
[47]
Kwon, S.U.; Cho, Y.J.; Koo, J.S.; Bae, H.J.; Lee, Y.S.; Hong, K.S.; Lee, J.H.; Kim, J.S. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke, 2005, 36(4), 782-786.
[http://dx.doi.org/10.1161/01.STR.0000157667.06542.b7] [PMID: 15746463]
[48]
Nazli, Y.; Colak, N.; Namuslu, M.; Erdamar, H.; Haltas, H.; Alpay, M.F.; Nuri Aksoy, O.; Olgun Akkaya, I.; Cakir, O. Cilostazol attenuates spinal cord ischemia-reperfusion injury in rabbits. J. Cardiothorac. Vasc. Anesth., 2015, 29(2), 351-359.
[http://dx.doi.org/10.1053/j.jvca.2014.06.028] [PMID: 25440635]
[49]
Nakamura, T.; Houchi, H.; Minami, A.; Sakamoto, S.; Tsuchiya, K.; Niwa, Y.; Minakuchi, K.; Nakaya, Y. Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta. Life Sci., 2001, 69(15), 1709-1715.
[http://dx.doi.org/10.1016/S0024-3205(01)01258-9] [PMID: 11665832]
[50]
Li, H.; Hong, D.H.; Son, Y.K.; Na, S.H.; Jung, W.K.; Bae, Y.M.; Seo, E.Y.; Kim, S.J.; Choi, I.W.; Park, W.S. Cilostazol induces vasodilation through the activation of Ca(2+)-activated K(+) channels in aortic smooth muscle. Vascul. Pharmacol., 2015, 70, 15-22.
[http://dx.doi.org/10.1016/j.vph.2015.01.002] [PMID: 25748552]
[51]
Liu, Y.; Shakur, Y.; Yoshitake, M.; Kambayashi Ji, J. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc. Drug Rev., 2001, 19(4), 369-386.
[http://dx.doi.org/10.1111/j.1527-3466.2001.tb00076.x] [PMID: 11830753]
[52]
Liu, Y.; Fong, M.; Cone, J.; Wang, S.; Yoshitake, M.; Kambayashi, J. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J. Cardiovasc. Pharmacol., 2000, 36(3), 351-360.
[http://dx.doi.org/10.1097/00005344-200009000-00011] [PMID: 10975593]
[53]
Shryock, J.C.; Belardinelli, L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am. J. Cardiol., 1997, 79(12A), 2-10.
[http://dx.doi.org/10.1016/S0002-9149(97)00256-7] [PMID: 9223356]
[54]
Lau, C.S.; McLaren, M.; Saniabadi, A.; Belch, J.J. Increased whole blood platelet aggregation in patients with Raynaud’s phenomenon with or without systemic sclerosis. Scand. J. Rheumatol., 1993, 22(3), 97-101.
[http://dx.doi.org/10.3109/03009749309099251] [PMID: 8316776]
[55]
Nomura, S.; Shouzu, A.; Omoto, S.; Hayakawa, T.; Kagawa, H.; Nishikawa, M.; Inada, M.; Fujimura, Y.; Ikeda, Y.; Fukuhara, S. Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes. Thromb. Haemost., 1998, 80(3), 388-392.
[PMID: 9759615]
[56]
Weintraub, W.S. The vascular effects of cilostazol. Can. J. Cardiol., 2006, 22(Suppl. B), 56B-60B.
[http://dx.doi.org/10.1016/S0828-282X(06)70987-4] [PMID: 16498513]
[57]
Cone, J.; Wang, S.; Tandon, N.; Fong, M.; Sun, B.; Sakurai, K.; Yoshitake, M.; Kambayashi, J.; Liu, Y. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J. Cardiovasc. Pharmacol., 1999, 34(4), 497-504.
[http://dx.doi.org/10.1097/00005344-199910000-00004] [PMID: 10511123]
[58]
Nietert, P.J.; Shaftman, S.R.; Silver, R.M.; Wolf, B.J.; Egan, B.M.; Hunt, K.J.; Smith, E.A. Raynaud phenomenon and mortality: 20+ years of follow-up of the Charleston Heart Study cohort. Clin. Epidemiol., 2015, 7, 161-168.
[http://dx.doi.org/10.2147/CLEP.S75482] [PMID: 25678814]
[59]
Rajagopalan, S.; Pfenninger, D.; Somers, E.; Kehrer, C.; Chakrabarti, A.; Mukherjee, D.; Brook, R.; Kaplan, M.J. Effects of cilostazol in patients with Raynaud’s syndrome. Am. J. Cardiol., 2003, 92(11), 1310-1315.
[http://dx.doi.org/10.1016/j.amjcard.2003.08.013] [PMID: 14636909]
[60]
Negrini, S.; Spanò, F.; Penza, E.; Rollando, D.; Indiveri, F.; Filaci, G.; Puppo, F. Efficacy of cilostazol for the treatment of Raynaud’s phenomenon in systemic sclerosis patients. Clin. Exp. Med., 2016, 16(3), 407-412.
[http://dx.doi.org/10.1007/s10238-015-0370-5] [PMID: 26088182]
[61]
Zheng, H.; Yang, H.; Gong, D.; Mai, L.; Qiu, X.; Chen, L.; Su, X.; Wei, R.; Zeng, Z. Progress in the Mechanism and Clinical Application of Cilostazol. Curr. Top. Med. Chem., 2019, 19(31), 2919-2936.
[http://dx.doi.org/10.2174/1568026619666191122123855] [PMID: 31763974]
[62]
Pletal 50 mg tablets summary of product characteristics. Available at: https://www.medicines.org.uk/emc/product/164/smpc#companyDetails (acceesed on: 24 March, 2021)
[63]
Wigley, F.M. Treatment of Raynaud phenomenon: initial management, Available at: https://www.uptodate.com/contents/treatment-of-raynaud-phenomenon-initial-management (acceesed on: 24 March, 2021)

Rights & Permissions Print Cite
Article Metrics
41
1
Wayfinder Image
Open Access Journals Promotions
World Antimicrobial Awareness Week
© 2024 Bentham Science Publishers | Privacy Policy